Bayer was granted an exclusive licence from ProStrakan to develop and commercialise testosterone gel Tostran for the treatment of male hypogonadism in 65 countries, the Scottish drugmaker reported Thursday. The agreement covers Canada, Latin America, the Middle East, Africa, Asia and the Pacific region.
[ad]
Under the terms of the partnership, Bayer will pay ProStrakan an unspecified [...]

Popularity: 3% [?]

Sanofi-aventis reported Thursday that an FDA advisory panel will review the company’s experimental atrial fibrillation drug Multaq (dronedarone) on March 18. The compound was granted priority review status by the US regulator in August, with a decision expected around January.
[ad]
Commenting on the news, Deutsche Bank analysts stated that “this is a further delay to the [...]

Popularity: 3% [?]

Some spokespeople for GlaxoSmithKline, sanofi-aventis, AstraZeneca, Daiichi Sankyo and Merck KGaA announced that the drugmakers suspended travel to India following terrorist attacks across Mumbai on November 26, Bloomberg reported Thursday.
[ad]
GlaxoSmithKline spokesperson Alice Hunt noted that the company cancelled travel to India in the coming days, but that the attacks will not affect the UK drugmaker’s [...]

Popularity: 4% [?]

Earlier this month the treatment was approved in Switzerland, where it will be marketed as Zevtera, and last week the EMEA’s Committee for Medicinal Products for Human Use recommended approval of the drug.

Popularity: 4% [?]

The National Institute for Health and Clinical Excellence on Wednesday issued final guidance recommending making Roche’s Tarceva (erlotinib) available on the NHS as an alternative to sanofi-aventis’ Taxotere (docetaxel) for the second-line treatment of patients with advanced non-small-cell lung cancer (NSCLC), on the condition that overall treatment costs for the product are equal to those [...]

Popularity: 4% [?]

BRUSSELS- Belgian biotechnology company Galapagos said on Wednesday it would partner with German peer MorphoSys AG to develop antibody drugs to treat bone and joint disease, sending both sets of shares higher.
[ad]
‘We finally have a great entry into this market without having to invest massively,’ Onno Van de Stolpe, Galapagos Chief Executive, said in a [...]

Popularity: 3% [?]

Here’s the big new cancer report, compiled by researchers from the American Cancer Society, the CDC and other august institutions.

Popularity: 4% [?]

Concerns about side effects of the potent antipsychotic Risperdal in kids are one reason for the intense interest in Johnson & Johnson’s funding of an academic institute that aimed to support use of the drug in youngsters.
[ad]
Side effects are especially worrisome for young people, whose bodies are still developing. Several doctors, concerned about overprescribing of [...]

Popularity: 3% [?]

Barbara Ryan, the outspoken drug analyst at Deutsche Bank, is out with a provocative report, even for her, on the need for drugmakers to get cracking on mergers. “Line up the usual suspects,” she writes.
We’ve certainly been down this road before and have thrown around plenty of possible pairings. But with two exceptions (Lilly-ImClone and [...]

Popularity: 4% [?]

AstraZeneca and Abraxis BioScience may terminate their co-promotion deal in the US for breast cancer drug Abraxane (paclitaxel), AstraZeneca announced Tuesday.
[ad]
Abraxis’ board will decide in early January whether or not the company should re-acquire exclusive US rights to the product. If the board approves ending the co-promotion deal, Abraxis will pay AstraZeneca a $268-million fee [...]

Popularity: 3% [?]